News

Moderna has begun its study examining its investigational norovirus vaccine, mRNA-1403, to determine its efficacy, safety and immunogenicity.

Carter Keller discusses the company's recent $135.2 million contract with BARDA to develop recombinant polyclonal antibody therapies targeting botulinum neurotoxins and an unspecified biothreat, highlighting their innovative approach to address emerging health threats.

In the second installment of a 2-part series on this form of guided therapy, the lead investigator describes findings and the potential of biomarkers in antibiotic stewardship.

Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.

Part 1 of James F Cummings, MD interview, discusses the trial's goals and highlights the vaccine's potential to generate mucosal immunity, its logistical advantages and ease of administration.

In part 1 of a 2-part story, an investigator discusses the use of procalcitonin and C-reactive protein guided protocols for community-acquired pneumonia (CAP).

This study highlights fidaxomicin’s advantages over vancomycin, including lower recurrence rates of CDI and higher sustained clinical responses.

Enanta Pharmaceuticals says its investigational therapy, EDP-323, was found to be safe and efficacious against the respiratory virus.

Stool antigen testing added to fecal immunochemical testing for colorectal cancer screening resulted in higher participation rates, yet showed no significant differences in gastric cancer incidence or mortality.

Jennifer Quinn, head of Global Value & Access, Debiopharm, offers insights on pull incentives and how they look to get more antibiotics to market.

This study revealed a significant decline in MSSA and a corresponding rise MRSA, particularly linked to COVID-19 social isolation measures.

The Centers for Disease Control and Prevention (CDC) says a return to normalcy and vaccination protection waning are likely causes.

Direct penicillin challenges carry a low risk of adverse reactions for individuals with a history of penicillin allergy, with a reaction frequency of only 3.5%.

In the third installment of our series on injectables, long-acting injectables offer new treatment and prevention options for HIV, especially benefiting patients who struggle with daily oral medications.

The CDC reports 59 listeriosis cases and 10 deaths across 19 states, urging vulnerable populations to avoid deli meats, especially Boar's Head liverwurst.

A novel test is looking to ascertain this diagnostic information quickly to aid clinicians in making a determination of infections and more efficiently prescribe antimicrobials.

A single dose of the mRNA-1273.222 vaccine demonstrated strong immune responses against various omicron subvariants and showed a favorable safety profile compared to existing vaccines.

With 26 cases confirmed and several fatalities, the African country is experiencing its first bout of the zoonotic disease.

The CDC recommends vaccination for pregnant individuals and the administration of the RSV antibody nirsevimab to infants under eight months.

Get caught up with the latest study information, feedback from people in the field, and news on the latest investigational therapies.

A systematic review and meta-analysis finds that hepatitis B (HBV) education led by healthcare providers had the greatest impact on testing uptake.

This week, a push for better care standards for C difficile, a survey shows low vaccination rates for respiratory viruses among Americans, Georgia achieves a reduction in chronic hepatitis C infections through collaborative efforts, and more.

A new algorithm in mass spectrometry-based peptidomics is making it easier to analyze complex biological data by grouping peptides into clusters.

Study finds this population saw a 45% reduction of ongoing symptoms in those with COVID-19 weeks later and who had received subsequent doses of the original monovalent vaccine.

The latest data highlight ibezapolstat’s effects on gut microbiome health and systemic exposure, crucial for CDI treatment, while also indicating its potential against Bacillus anthracis, prompting plans for a bioterrorism development initiative.

An English modeling study suggests level of protection decreases only very slightly over time and reminds parents to have their children up to date on all vaccinations.

Study halted due to ineffective results, but the findings still provide valuable insights for future research and improve treatment strategies for those affected by CDI.

The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.

Tina Tan, MD, FAAP, FIDSA, FPIDS underscores the importance of education and global collaboration in antimicrobial stewardship to tackle the escalating threat of AMR, and her takeaways from the UN General Assembly High-Level Meeting on Antimicrobial Resistance.

Maryann Webb’s harrowing, personal experience with C diff, along with her professional work with federal agencies has prepared her for a life in advocacy with the Peggy Lillis Foundation. She wants to see the fecal microbiota transplant become more accessible and is working with Congress to make the infection a notifiable infectious disease.